echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Reduces risk of death by 59% antibody conjugate drug Trodelvy Breast Cancer Phase 3 Clinical End

    Reduces risk of death by 59% antibody conjugate drug Trodelvy Breast Cancer Phase 3 Clinical End

    • Last Update: 2020-07-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Triple-negative breast cancer (TNBC) is an invasive form of breast cancer, accounting for 20% of all breast cancersIt is more common in young and premenopausal womenTNBC cells do not express estrogen, progesterone receptors, or human epidermal growth factor receptors 2 (HER2), which means that drugs that target these receptors are generally ineffective in TNBCThere is currently no approved standard treatment for previously treated mTNBC patientsTrodelvy is an antibody coupling drug (ADC) that targets Trop-2 antigens, a cell surface protein expressed in many solid cancersTrodelvy kills cancer cells by binding to Trop-2 and delivering the anti-cancer drug SN-38note that on April 29 last year, Everest Medicines, a biopharmaceutical company funded by C-Bridge Capital, announced an exclusive licensing agreement with Immunomedic to acquire the development, registration and commercialization of the innovative antibody conjugate dating drug in Greater China, South Korea and some Southeast Asian countries and regionsThe total value of the partnership is up to $835 million, China's State Drug Administration Drug Review Center (CDE) recently announced that Genting Xinyao company submitted this antibody conjugate drug in China approved a clinical, indications of "received at least 2 lines of past treatment of metastatic triple-negative breast cancer."Photo Source: CDE Website ScreenshotIn the ASCENT study, more than 500 patients with metastatic triple-negative breast cancer were randomly treated with chemotherapy chosen by Trodelvy or a doctor who had received at least two metastatic diseasesThe results showed that Trodelvy reduced the patient's risk of disease progression or death by 59% compared to chemotherapy (HR-0.41, 95% CI, 0.32-0.52)The median PFS for patients treated by Trodelvy was 5.6 months (95% CI, 4.3-6.3) and chemotherapy was 1.7 months (95% CI, 1.5-2.6) (p 0.0001)Trodelvy also reached key secondary endpoints of the study, including total survival and objective remission rates, and the full results will be presented at the upcoming medical conference" Global Phase 3 clinical trial ASCENT's results confirm our preliminary observation that sacituzumab govitecan may change mTNBC's standard treatment." DrAditya Bardia, a professor of medicine at Harvard Medical School and lead the clinical trial, saidReferences:.™Retrieved July 6, 2020, fromOriginal Title: Reducing disease progression risk in patients with triple-negative breast cancer 59%, innovative antibody conjugate drugs reach phase 3 clinical endpoint
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.